Regular Article
Adriamycin Conjugates of Human Transferrin Bind Transferrin Receptors and Kill K562 and HL60-Cells

https://doi.org/10.1006/abbi.1993.1048Get rights and content

Abstract

Adriamycin (ADR) was coupled to human transferrin (TUF) by using a glutaraldehyde crosslinking method. The TRF-ADR conjugates were separated by column chromatography and the molar ratio of ADR to TRE (i.e., conjugation number) for the studied conjugates was found to be 1.2. Analysis in sodium dodecyl sulfate-polyacrylamide gels demonstrated that TRF-ADR conjugates with this molar ratio had the same mobility as native TRF and contained few aggregates. The ADR remained conjugated to TRF under conditions of decreased pH known to occur in many intracellular compartments, and analysis by spectrofluorometry revealed that the conjugated ADR retained its ability to intercalate DNA. The TRF-ADR conjugates were shown by flow cytometry to preferentially bind tumor cells and cell-bound conjugates were found to be laterally mobile within plasma membranes. The binding of TRF-ADR conjugates was determined to be saturable, and competition experiments done with both radioiodinated and fluorescein-labeled TRF-ADR conjugates demonstrated dose-dependent inhibition of conjugate binding by unlabeled TRF, indicating that TRF-ADR conjugates were bound by TRF receptors. Cytotoxicity studies performed with tritiated thymidine incorporation and tetrazolium reduction assays revealed that TRF-ADR conjugates inhibited the proliferation of both K562 and HL6O cells in culture more effectively than free ADR. Such conjugates could provide a delivery system for ADR that would target the drug and possibly diminish its dose-associated complications.

References (0)

Cited by (36)

  • Transferrin and transferrin receptors update

    2019, Free Radical Biology and Medicine
    Citation Excerpt :

    For example, single-chain fragments of the variable region targeting TfR1 with flexible linkers for conjugation with drugs have been developed, and clinical trials are being conducted to evaluate the safety and efficacy of these constructs in patients with cancer, demonstrating promising results [158]. Various Tf conjugates are used in drug and gene delivery systems [159]; among them, doxorubicin conjugated with Tf was shown to be selectively toxic to a variety of cancer cells [160–164]. This system may be effective for brain tumors because TfR1 is expressed on the blood brain barrier and is often over expressed in brain tumors.

  • The transferrin receptor and the targeted delivery of therapeutic agents against cancer

    2012, Biochimica et Biophysica Acta - General Subjects
    Citation Excerpt :

    ADR is a widely used chemotherapy in treating many forms of cancer, but ultimately exhibits severe side effects, including cardiotoxicity, myelosuppression, nephrotoxicity, extravasation, and bone marrow depression due to quick diffusion throughout the body [22]. To circumvent the adverse affects of ADR, it has been chemically conjugated to Tf in an effort to deliver it directly to cancer cells expressing high levels of TfR [23–26], resulting in an effectual tissue distribution, a prolonged half-life of ADR in blood, and controlled release from Tf [25]. This Tf–ADR conjugate has shown cytotoxicity in vitro against a variety of malignant human cell lines, including Lovo (colorectal adenocarcinoma), H-MESO-1 (mesothelioma), Hep2 (liver carcinoma), HL-60 (promyelocytic leukemia), K562 (erythroleukemia), HeLa (cervical adenocarcinoma), U-937 (histiocytic lymphoma), LXFL (lung carcinoma), and MDA-MB-428 (breast cancer) and the murine fibroblast cell line L929 [23–25,27–30].

  • Inhibition of transferrin iron release increases in vitro drug carrier efficacy

    2007, Journal of Controlled Release
    Citation Excerpt :

    DT was selected as a cytotoxin since the effective concentration range of DT (IC50 ~ 0.1 nM) [7] is consistent with the concentration range in which increases in cellular association were observed in the cellular trafficking assay (0.1 and 1 nM, Fig. 4). This is in contrast to cytotoxins such as adriamycin, whose effective concentration range is considerably higher (IC50 ~ 1 μM) [27]. Thus, oxalate Tf conjugates with these cytotoxins would not be expected to display increased efficacy, since differences in cellular association between oxalate Tf and native Tf diminish as concentrations rise to 10 nM (Fig. 4C).

View all citing articles on Scopus
View full text